EGFR and classic lissencephaly: The presence of pre‐existing interstitial lung abnormal shadow (pre‐ILS) has repeatedly demonstrated the risk of lung injury with systemic chemotherapy, PD‐1/L1 inhibitors,6, 7, 8 or EGFR‐TKIs6, 9; the incidence of the lung injury in patients with pre‐ILS who received gefitinib was as high as 14%–33%.9, 10